Please try another search
For the six months ended 30 June 2017, Kite Pharma Inc revenues increased 100% to $19.9M. Net loss increased 85% to $200.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Other Research and Development increase from $25.9M to $111M (expense), Other General and Administrative increase from $10.1M to $53.4M (expense).
Period Ending: | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 |
---|---|---|---|---|
Total Revenue | 10.05 | 9.84 | 4.91 | 7.34 |
Gross Profit | ||||
Operating Income | -101.92 | -91.91 | -86.37 | -74.95 |
Net Income | -109.82 | -90.4 | -84.94 | -73.95 |
Period Ending: | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 |
---|---|---|---|---|
Total Assets | 907.11 | 923.74 | 524.3 | 584.52 |
Total Liabilities | 197.86 | 143.65 | 96.33 | 90.16 |
Total Equity | 709.25 | 780.1 | 427.97 | 494.35 |
Period Ending: | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | -52.68 | -17.81 | -168.9 | -114.99 |
Cash From Investing Activities | -345.89 | 51.18 | -112.94 | -150.21 |
Cash From Financing Activities | 431.66 | 417.19 | 3.69 | 1.11 |
Net Change in Cash | 33.27 | 450.59 | -278.28 | -264.09 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review